1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Pfizer funds "new model" of unbiased CME in US with $3 million to Stanford

 
• By Nancy Faigen

Stanford University School of Medicine is developing new continuing medical education (CME) courses for physicians which are free from influence from the pharmaceutical industry, despite being funded by a three-year, $3 million grant from Pfizer. But the move has not put to rest the ongoing controversy over how to fund US CME, in which doctors are required to participate on a regular basis.

Stanford University School of Medicine is developing new continuing medical education (CME) courses for physicians which are free from influence from the pharmaceutical industry, despite being funded by a three-year, $3 million grant from Pfizer. But the move has not put to rest the ongoing controversy over how to fund US CME, in which doctors are required to participate on a regular basis.

According to Stanford, Pfizer will have no say in how the funds are spent. Rather, the funds will be used...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

More from Therapeutic Category

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.